AryoGen Bevacizumab Biosimilar Compares To Avastin

Iranian Player Has Ambitions In Biotech Space

Iranian player AryoGen has received a boost after a recent study revealed that the firm’s bevacizumab biosimilar was non-inferior to reference product Avastin terms of efficacy and tolerability.

Azadi_Tower_Iran
Tehran-based AryoGen has received a boost for bevacizumab • Source: Shutterstock

AryoGen Pharmed’s BE1040V biosimilar bevacizumab candidate has demonstrated comparable efficacy and tolerability to Genentech’s reference product, Avastin, according to the results of a Phase III clinical study in patients with metastatic colorectal cancer published in Clinical Therapeutics.

The trial for the Iranian player, which is to market its biosimilar under the Stivant name, involved 126 patients administered...

Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Biosimilars

More from Products

  • For Generics, A Victory Lap – And A Warning – On Drug Shortages

    Avoiding disaster at the beginning of the pandemic and offering a pro-active supply chain blueprint should position the generics industry well for an onshoring debate in Congress, but a look back at March 2020 is a reminder that even small policy shifts can have a big impact.

  • GB-Free-Company-The Secret to Walking More: It’s Not Counting Steps

    We’ve all been told that walking 10,000 steps a day is the magic number for better health. But what if the real secret to walking more isn’t about counting steps at all? In this article, we explore how focusing on motivation, environment, and mindset can help you build a walking habit that lasts.

  • Biocon And Teva Sign Up To Biosimilars Forum

    Teva and Biocon Biologics have become the latest firms to sign up to the Biosimilars Forum industry association in the US.